Ginkgo Bioworks Holdings, INC Form 4 insider transactions

Director Christian O. Henry reports acquisition of shares and derivative securities in Ginkgo Bioworks Holdings, Inc. following vesting of restricted stock units and grant of new awards.

Director Kathy Hopinkah Hannan reports acquisition and vesting of restricted stock units and stock options in Ginkgo Bioworks Holdings, Inc.

Director Arie Belldegrun reports acquisition and disposal of Class A Common Stock and derivative securities in Ginkgo Bioworks Holdings, Inc.

Director Reshma Kewalramani reported the vesting of restricted stock units into Class A Common Stock of Ginkgo Bioworks Holdings, Inc.

Director Marijn E Dekkers reports acquisition and disposal of Class A Common Stock and vesting of Restricted Stock Units (RSUs) in Ginkgo Bioworks Holdings, Inc.

Director Myrtle S. Potter reports the acquisition of stock options and restricted stock units (RSUs) in Ginkgo Bioworks Holdings, Inc.

Director Ross Fubini reports the acquisition of stock options and restricted stock units (RSUs) in Ginkgo Bioworks Holdings, Inc. related to director compensation.

Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., sold shares to cover tax withholding obligations related to vesting restricted stock units.

Mark Dmytruk, CFO of Ginkgo Bioworks Holdings, reports multiple transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions.

Director Marijn E Dekkers of Ginkgo Bioworks Holdings, Inc. reports selling 265,000 shares of Class A Common Stock at an average price of $0.8303 on May 16, 2024.

Director Shyam Sankar of Ginkgo Bioworks Holdings, Inc. recently purchased 625,000 shares of Class A Common Stock at an average price of $0.8236 per share.

Director Harry Sloan increased his stake in Ginkgo Bioworks by purchasing 297,619 shares of Class A Common Stock at an average price of $0.9133 on May 14, 2024.

Director Marijn E. Dekkers of Ginkgo Bioworks Holdings, Inc. reports the sale of 1,727,056 shares of Class A Common Stock at $0.93 per share on May 14, 2024.

Mark Dmytruk, CFO of Ginkgo Bioworks Holdings, reports multiple transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions, according to a Form 4 filing with the SEC.

Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., sold shares to cover tax withholding obligations following the vesting of restricted stock units.

Barry Canton, a director at Ginkgo Bioworks Holdings, was granted 10 million stock options with vesting tied to both time and the achievement of specific stock price targets.

Reshma Shetty, a Director, Officer, and 10% Owner of Ginkgo Bioworks Holdings, was granted 10 million stock options tied to performance-based vesting criteria.

Ginkgo Bioworks CEO Jason R. Kelly was granted 5,000,000 stock options tied to performance-based vesting criteria related to stock price hurdles.

Ginkgo Bioworks CFO Mark Dmytruk reports acquisition and disposal of Class A Common Stock and Restricted Stock Units, including sales to cover tax obligations.

Ginkgo Bioworks CFO Mark Dmytruk was granted 1,100,000 Restricted Stock Units (RSUs) that vest monthly over four years, as reported in a Form 4 filing with the SEC.

Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., reports the acquisition of 300,000 Restricted Stock Units (RSUs) on March 7, 2024, vesting over a period beginning May 1, 2024.

Mark Dmytruk, CFO of Ginkgo Bioworks Holdings, Inc., reports transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions.